Clinical trials: Haematological Malignancies
Geriatric, Haematologic Neoplasm
Feasibility of Physical Activity in Older Adults With Haematological Malignancies: ACCES Study
The aim of this study is to implement a simple and unsupervised home-based physical activity (PA) program for cancer patients in 2 oncogeriatric units in Toulouse Hospital (day hospital and week hospital).
- Trial name
- ACCES (NCT06102876)
- Testing
- Physical activity (PA) program
- Where
- France
- Volunteers
- 69 people
- Sponsor
- University Hospital, Toulouse
Myelodysplastic Syndromes, Leukemia Myeloid Acute
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
This is a post-authorization, retrospective multicentre observational nationwide study (PAS-OD). It will be conducted by reviewing medical records and database of patients who participated in the validation of the psychometric…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT02842229
- Where
- 15 sites in Spain
- Volunteers
- 117 people
- Sponsor
- Celgene
Invasive Aspergillosis in Patients With Onco-haematological Diseases
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis
The purpose of this study is to evaluate the performances of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
- Trial name
- MYCOGENIE (NCT03349931)
- Testing
- DNA extraction and detection of Aspergillus fumigatus in serum samples
- Where
- 6 sites in France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Diseases, Hematological Malignancies
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
- Conditions
- Hematological Diseases, Hematological Malignancies, Blood Diseases, Malignant Lymphoma
- Trial name
- Bismuth-PBH (NCT00892502)
- Testing
- Bismuth tablets
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Copenhagen University Hospital at Herlev
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT05770037)
- Testing
- Alectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Thrombocytopaenia, Haematological Malignancies
Clinical Efficacy of Platelet Transfusion
The aim of this study is to analyze the effect of the storage time of platelet concentrates on the occurrence of bleeding events during prophylactic platelet transfusions in patients with hematological malignancies.
- Trial name
- ECLAT (NCT06805097)
- Testing
- Self-assessment of bleeding events
- Where
- France
- Volunteers
- 343 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Malnutrition, Lymphoma
Predictors of Malnutrition in Patients With Haematological Cancer
The primary purpose of this study is to conduct an exploratory study of which predictors are most significant for LBM loss in patients with lymphoma.
- Trial name
- NCT05209321
- Where
- Denmark
- Volunteers
- 62 people
- Sponsor
- Jens Rikardt Andersen
Polycythemia Vera, Essential Thrombocythemia
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic…
- Trial name
- NCT00866762
- Testing
- HDAC inhibitor (MK-0683)
- Where
- 16 sites in Denmark, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Leukemia, Chronic Myeloid Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell…
- Conditions
- Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Diffuse Large Cell Lymphoma
- Trial name
- AlloTreo (NCT00598624)
- Testing
- Treosulfan IV
- Where
- 12 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS San Raffaele
Cancer, Hematologic Malignancy
Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy
There are no recommendations and few studies on the monitoring of fragile patients in the oncological treatment, both on the organizational arrangements on its interest in the prevention of functional deterioration of the patient…
- Trial name
- TelOG (NCT02583035)
- Testing
- Nurse telephone contact
- Where
- 5 sites in France
- Volunteers
- 131 people
- Sponsor
- Centre Francois Baclesse
Hematopoietic/Lymphoid Cancer
Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of abnormal cells.
- Trial name
- NCT00959231
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- 6 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Hematological Malignancies, Allogeneic Transplantation
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA).
- Trial name
- NCT00129155
- Testing
- treosulfan
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Haematological Malignancy, Malignancy
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called…
- Conditions
- Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders
- Trial name
- DETERMINE (NCT05770544)
- Testing
- Entrectinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Hematological Malignancies
Molecular Disease Profile of Hematological Malignancies
In this prospective multicentric study, the University of Pavia together with the Fondazione IRCCS Policlinico San Matteo, Pavia and the IRCCS Fondazione Maugeri, Pavia, Italy will provide a systematic analysis of gene mutations…
- Trial name
- RELab1 (NCT02459743)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- University of Pavia
Acute Myeloid Leukemia, Myelodysplastic Syndrome
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
This phase I trial studies the side effects and best dose of anti-cluster of differentiation (CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies including acute myeloid leukemia that has…
- Trial name
- NCT02678338
- Testing
- Hu5F9-G4
- Where
- 5 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Haematological Malignancy, Acute Leukemia
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes haemoglobinopathies, bone…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT05298930)
- Testing
- Physical activity program
- Where
- France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre Leon Berard
Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
The purpose of the CARMic study is to investigate whether a restrictive, microbiome-sparing antibiotic strategy can better preserve the gut microbiota in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy…
- Conditions
- Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota
- Trial name
- CARMic (NCT07842198)
- Testing
- ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Haematologic Disease, Haematological Malignancy
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
Exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may…
- Trial name
- INTHEMA (NCT04298892)
- Testing
- clinical data and sample collection
- Where
- 26 sites in Italy
- Volunteers
- 2,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Cancer, Oncology
Seen and Be Heard: Ensuring Fair Cancer Care for All Children
Introduction: Research has routinely been conducted into the experiences and well-being of children and young people with cancer and their families.
- Conditions
- Cancer, Oncology, Haematological Malignancy
- Trial name
- NCT06481527
- Volunteers
- 50 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust